India welcomed the expiration of the Simecrolimus patent this Saturday, and many pharmaceutical companies are "watching eagerly".

With the patent protection for the best-selling weight loss drug under the banner of Novo Nordisk expiring in India early Saturday morning, a "GLP-1 generic drug war" is looming. Indian listed company Natco Pharma announced that they will launch a generic drug on the first day of the expiration of the semaglutide patent, with the price for the multi-dose bottle version starting at 1290 Indian rupees per month. According to announcements from Indian listed companies and records from financial results conference calls, including Sun Pharma, Dr. Reddy's Laboratories, and at least 12 other large Indian pharmaceutical companies have confirmed that they will launch generic versions of semaglutide in the near future, but the actual scale of competition will be much larger.